• Optimising the selection of antiretroviral drugs for patients experiencing virological failure remains a challenge • This is particularly true in resource-limited settings where the latest drugs may not be accessible and/or genotyping may not be affordable to guide drug selection • The RDI was set up in 2002 to develop computational models that predict virological response to different combinations of drugs, and to make those models freely available to assist optimal, individualised drug selection.
Background
• Optimising the selection of antiretroviral drugs for patients experiencing virological failure remains a challenge • This is particularly true in resource-limited settings where the latest drugs may not be accessible and/or genotyping may not be affordable to guide drug selection • The RDI was set up in 2002 to develop computational models that predict virological response to different combinations of drugs, and to make those models freely available to assist optimal, individualised drug selection.
Methods
• In order to collect sufficient data to develop such models, HIV cohorts and clinics around the world were approached for a range of longitudinal clinical, virological and treatment data for their patients • These data have been used to train a range of neural network, support vector machine, linear regression and random forest models 
